The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis
Abstract
Antinuclear antibodies (ANA) staining nuclear dot structures predominantly occur in primary biliary cirrhosis (PBC) patients and recognize the Sp100 and promyelocytic leukemia protein (PML). From retrospective analysis of sera from a clinically well-defined Canadian series of 170 PBC patients included into a 24-month therapeutic trial of ursodeoxycholic acid (UDCA), we report the prevalence of these ANA and their dynamics in the course of the disease. Using an enzyme-linked immunosorbent assay (ELISA), anti-Sp100 autoantibodies were shown in 35 (21%) patients. Thirty-three patients (19%) had autoantibodies against PML as determined by indirect immunostaining of cells overexpressing PML. Altogether, anti-nuclear dot autoantibodies were present in 25% of the 170 PBC patients. Their occurrence correlated with an unfavorable disease course, because these patients progressed significantly more frequently from early stages (I/II) to late stages (III/IV) within the 24-month observation period (P < .05). During the course of the disease, the autoantibody levels against the Sp100 full-length protein remained nearly constant in all 35 positive patients. However, 9 patients showed remarkable changes in Sp100 epitope recognition as revealed by ELISA and immunoblotting. When the occurrence of these changes and the treatment of the patients were compared retrospectively, it became evident that 8 of the 9 patients had received UDCA (42% of all Sp100-positive patients treated with UDCA). These findings indicate subtle changes of the Sp100 epitope recognition pattern during the natural course of the disease and its induction or acceleration by UDCA treatment. This implies that UDCA can modulate immunoglobulin (Ig) expression not only quantitatively, but also qualitatively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.
Gossen, M., & Bujard, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5547 · Cited by 4,943
Antinuclear Antibodies: Diagnostic Markers for Autoimmune Diseases and Probes for Cell Biology
Tan, E. M. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60641-0 · Cited by 1,514
de Thé, H., Chomienne, C., Lanotte, M., Degos, L., & Dejean, A. (1990) · Nature · doi:10.1038/347558a0 · Cited by 1,355
A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
Dyck, J. A., Maul, G. G., Miller, W. H., Chen, J. D., Kakizuka, A., & Evans, R. M. (1994) · Cell · doi:10.1016/0092-8674(94)90340-9 · Cited by 785
Weis, K., Rambaud, S., Lavau, C., Jansen, J., Carvalho, T., Carmo-Fonseca, M., Lamond, A., & Dejean, A. (1994) · Cell · doi:10.1016/0092-8674(94)90341-7 · Cited by 652
The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion.
Koken, M. H., Puvion-Dutilleul, F., Guillemin, M. C., Viron, A., Linares-Cruz, G., Stuurman, N., de Jong, L., Szostecki, C., Calvo, F., & Chomienne, C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06356.x · Cited by 499
Self-citationAutoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis
Wesierska-Gadek, J., Hohenuer, H., Hitchman, E., & Penner, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8608894 · Cited by 386
Autoantibodies Against “Nuclear Dots” in Primary Biliary Cirrhosis
Szostecki, C., Guldner, H., & Will, H. (1997) · Seminars in Liver Disease · doi:10.1055/s-2007-1007184 · Cited by 384
Self-citationSZOSTECKI, C., WILL, H., NETTER, H. J., & GULDNER, H. H. (1992) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1992.tb03224.x · Cited by 364
Self-citationMaul, G. G., Guldner, H. H., & Spivack, J. G. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-12-2679 · Cited by 315
Cited by
Nakamura, M., Kondo, H., Mori, T., Komori, A., Matsuyama, M., Ito, M., Takii, Y., Koyabu, M., Yokoyama, T., Migita, K., et al. (2007) · Hepatology · doi:10.1002/hep.21472 · Cited by 365
Selmi, C., Bowlus, C. L., Gershwin, M. E., & Coppel, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61965-4 · Cited by 334
Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis
Wesierska-Gadek, J., Penner, E., Battezzati, P. M., Selmi, C., Zuin, M., Hitchman, E., Worman, H. J., Gershwin, E. M., Podda, M., & Invernizzi, P. (2006) · Hepatology · doi:10.1002/hep.21172 · Cited by 177
Rigopoulou, E. I., Davies, E. T., Pares, A., Zachou, K., Liaskos, C., Bogdanos, D.-P., Rodes, J., Dalekos, G. N., & Vergani, D. (2005) · Gut · doi:10.1136/gut.2003.036558 · Cited by 134
Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis
Czaja, A. J., Muratori, P., Muratori, L., Carpenter, H. A., & Bianchi, F. B. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0924.x · Cited by 89
Metadata
- Authors
- Züchner, D., Sternsdorf, T., Szostecki, C., Heathcote, E. J., Cauch-Dudek, K., & Will, H.
- Venue
- Hepatology
- Published
- 1997-11
- Volume
- 26
- Issue
- 5
- Pages
- 1123-1130
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W4232630289
- Cited by
- 404
- References
- 34
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. https://app.cochat.ai/papers/10.1002/hep.510260506
- The paper
- Züchner, D., Sternsdorf, T., Szostecki, C., Heathcote, E. J., Cauch-Dudek, K., & Will, H. (1997). Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology. https://doi.org/10.1002/hep.510260506
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
